FDA approves Cordis' rapid-exchange heparin-coated stent:
This article was originally published in Clinica
Executive Summary
The US FDA has approved Cordis' heparin-coated coronary stent for use on a rapid-exchange delivery system, called Raptorail. The Bx Velocity coronary stent with HEPACOAT was first approved for over-the-wire delivery in November 2000, when it became the first drug-coated stent to receive regulatory approval, says Cordis, a Johnson & Johnson firm.